October 20, 2022

WuXi Global Forum 2023

Date and time

January 10, 2023 ~ January 10, 2023

1:30PM-6:00PM PST

Location

San Francisco

Dear Colleagues & Friends,

It was a great honor for us to host many of you from around the world in San Francisco for the 11th annual WuXi Global Forum on January 10th, 2023. The theme of this year’s forum was B.O.L.D. where we reflected on the state of innovation and highlighted our industry’s notable advances in tackling innovation challenges to build an impactful future for patients: Breaking Barriers, Opening New Horizons, Leading Next Generation, and Delivering on the promise for patients.

To our esteemed guest speakers, THANK YOU for leading the way with new thinking and actionable approaches as we work together to shape the future of healthcare.

Special thanks to our supportive partners: A*STAR, BioCentury, Biocom California, BioWorld, California Life Sciences, Davos Alzheimer’s Collaborative, GEN, Medicon Valley Alliance, QB3, Swiss Biotech Association, UC Berkeley incubator Bakar Labs and UK BioIndustry Association.

Agenda

01:00 PM - 01:30 PM Onsite Check-in and Networking
01:30 PM - 01:35 PM Welcome
Hui Cai, Program Chair and Vice President, WuXi AppTec
01:35 PM - 01:45 PM Opening Remarks
Minzhang Chen, Co-CEO, WuXi AppTec
01:45 PM - 02:30 PM State of Innovation 2023
Todd Golub, Director, Broad Institute of MIT & Harvard
John Ngai, Director, NIH BRAIN Initiative
Vijay Pande, General Partner, Andreessen Horowitz
Aviv Regev, Head, Genentech Research and Early Development
Michael Severino, CEO, Tessera Therapeutics; CEO-Partner, Flagship Pioneering
Session Leader: Mathai Mammen, Executive Vice President of R&D, Johnson & Johnson Pharmaceuticals (in transition)
02:30 PM - 03:10 PM Breaking Barriers: Druggability Redefined
Ros Deegan, CEO, OMass Therapeutics
Dan Nomura, Professor of Chemical Biology and Molecular Therapeutics, University of California, Berkeley
Nancy Pryer, CSO, Ambagon Therapeutics
Lance Stewart, Chief Strategy and Operations Officer, Institute for Protein Design, University of Washington
Session Leader: Karen Tkach Tuzman, Senior Editor and Head of Discovery & Preclinical Development, BioCentury
03:10 PM - 03:50 PM Opening New Horizons: Spotlight on RNA Therapeutics
Tom Barnes, CEO, Orna Therapeutics
John Mendlein, Chairman, Laronde; Executive Partner, Flagship Pioneering
Romesh Subramanian, CEO, Ascidian Therapeutics
Michelle Werner, CEO, Alltrna; CEO-Partner, Flagship Pioneering
Session Leader: Nina Kjellson, General Partner, Canaan
03:50 PM - 04:30 PM Leading Next Generation of Cell and Gene Therapies
Ken Drazan, Chairman, CEO, Co-Founder, ArsenalBio
Keith Gottesdiener, President & CEO, Prime Medicine
Laura Shawver, President & CEO, Capstan Therapeutics
Catherine Stehman-Breen, CEO, Chroma Medicine
Session Leader: Edward Hu, Vice Chairman, Global Chief Investment Officer, WuXi AppTec
04:30 PM - 05:05 PM Delivering on the Promise for Patients
Giulio Draetta, SVP & CSO, MD Anderson Cancer Center
Stephen Hauser, Director, UCSF Weill Institute for Neurosciences; Professor, Department of Neurology, University of California, San Francisco
Joseph Wu, Director of Stanford Cardiovascular Institute; President-Elect of American Heart Association
Session Leader: Christiana Bardon, Co-Managing Partner of BioImpact Capital, an MPM affiliate
05:05 PM - 05:50 PM Building An Impactful Future
Juergen Eckhardt, SVP & Head of Leaps by Bayer
Sofia Ioannidou, Partner, Andera Partners
Carol Suh, Partner, ARCH Venture Partners
Sze-Wee Tan, Assistant Chief Executive, Innovation and Enterprise Group, Singapore Agency for Science, Technology and Research (A*STAR)
Session Leader: Michal Preminger, Regional Head, Johnson & Johnson Innovation East North America
05:50 PM - 06:00 PM Closing Remarks
Steve Yang, Co-CEO, WuXi AppTec
06:00 PM - 07:00 PM Networking Reception

Speakers

Hui Cai
PROGRAM CHAIR AND VICE PRESIDENT, WUXI APPTEC
Minzhang Chen
CO-CEO, WUXI APPTEC
Todd Golub
DIRECTOR, BROAD INSTITUTE OF MIT & HARVARD
John Ngai
DIRECTOR, NIH BRAIN INITIATIVE
Vijay Pande
GENERAL PARTNER, ANDREESSEN HOROWITZ
Aviv Regev
HEAD, GENENTECH RESEARCH AND EARLY DEVELOPMENT
Michael Severino
CEO, TESSERA THERAPEUTICS; CEO-PARTNER, FLAGSHIP PIONEERING
Mathai Mammen
EXECUTIVE VICE PRESIDENT OF R&D, JOHNSON & JOHNSON PHARMACEUTICALS (IN TRANSITION)
Ros Deegan
CEO, OMASS THERAPEUTICS
Dan Nomura
PROFESSOR OF CHEMICAL BIOLOGY AND MOLECULAR THERAPEUTICS, UNIVERSITY OF CALIFORNIA, BERKELEY
Nancy Pryer
CSO, AMBAGON THERAPEUTICS
Lance Stewart
CHIEF STRATEGY AND OPERATIONS OFFICER, INSTITUTE FOR PROTEIN DESIGN, UNIVERSITY OF WASHINGTON
Karen Tkach Tuzman
SENIOR EDITOR AND HEAD OF DISCOVERY & PRECLINICAL DEVELOPMENT, BIOCENTURY
Tom Barnes
CEO, ORNA THERAPEUTICS
John Mendlein
CHAIRMAN, LARONDE; EXECUTIVE PARTNER, FLAGSHIP PIONEERING
Romesh Subramanian
CEO, ASCIDIAN THERAPEUTICS
Michelle Werner
CEO, ALLTRNA; CEO-PARTNER, FLAGSHIP PIONEERING
Nina Kjellson
GENERAL PARTNER, CANAAN
Ken Drazan
CHAIRMAN, CEO, CO-FOUNDER, ARSENALBIO
Keith Gottesdiener
PRESIDENT & CEO, PRIME MEDICINE
Laura Shawver
PRESIDENT & CEO, CAPSTAN THERAPEUTICS
Catherine Stehman-Breen
CEO, CHROMA MEDICINE
Edward Hu
VICE CHAIRMAN, GLOBAL CHIEF INVESTMENT OFFICER, WUXI APPTEC
Giulio Draetta
SVP & CSO, MD ANDERSON CANCER CENTER
Stephen Hauser
DIRECTOR, UCSF WEILL INSTITUTE FOR NEUROSCIENCES; PROFESSOR, DEPARTMENT OF NEUROLOGY, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Joseph Wu
DIRECTOR OF STANFORD CARDIOVASCULAR INSTITUTE; PRESIDENT-ELECT OF AMERICAN HEART ASSOCIATION
Christiana Bardon
CO-MANAGING PARTNER OF BIOIMPACT CAPITAL, AN MPM AFFILIATE
Juergen Eckhardt
SVP & HEAD OF LEAPS BY BAYER
Sofia Ioannidou
PARTNER, ANDERA PARTNERS
Carol Suh
PARTNER, ARCH VENTURE PARTNERS
Sze-Wee Tan
ASSISTANT CHIEF EXECUTIVE, INNOVATION AND ENTERPRISE GROUP, SINGAPORE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
Michal Preminger
REGIONAL HEAD, JOHNSON & JOHNSON INNOVATION EAST NORTH AMERICA
Steve Yang
CO-CEO, WUXI APPTEC